A novel botulinum toxin type A that could potentially compete with Botox, DaxibotulinumtoxinA for Injection (DAXI), is currently under Biologics License Application (BLA) review in the US.

Under this agreement Aji Bio-Pharma will serve as a dual supply source and provide drug product manufacturing services for Revance at the company’s aseptic manufacturing facility in San Diego, California.

Read the full article at www.biopharma-reporter.com